Skip to main content
Premium Trial:

Request an Annual Quote

Eone-Diagnomics, GPBio Partner to Expand Genomic Data on Asian Populations

NEW YORK (GenomeWeb) – Eone-Diagnomics Genome Center (EDGC) has signed a strategic partnership agreement with GPBio, a Chinese genetic analysis company, to develop and expand consumer and clinical genomic services for the Asian markets.

EDGC is a joint venture between Diagnomics — a San Diego, California-based bioinformatics firm — and South Korea's Eone Life Science Institute. It provides clinical and consumer genetic services, including noninvasive prenatal testing, newborn genetic screening, a DTC test called Gene2me, and an ophthalmology genetic test. GPBio, which is based Beijing and Shanghai, partners with Fudan University, Beijing University, and Tsinghua University.

The goal of the agreement is to build up genomic data from Asian populations to enable better interpretation.

"Much of the current genomics industry is being developed around the western countries such as the US and Europe," EDGC CEO Min Lee said in a statement. "With this agreement, however, it is highly expected that EDGC takes the lead in shaping and expanding the global genomics market by strengthening our market dominance in Asia's most potent market." 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.